Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. chlorpromazine, methylphenidate. Risk of acute hypertensive episode. restrictions. Risk of acute hypertensive episode. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Risk of acute hypertensive episode. Risk of acute hypertensive episode. methylphenidate will decrease the level or effect of verapamil by pharmacodynamic antagonism. Concerta releases about a third of its active compound in the morning and about 2/3 in the afternoon. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Potential for additive CNS stimulation. Monitor Closely (1)albuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. levalbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)epinephrine racemic and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. lisdexamfetamine increases effects of methylphenidate by pharmacodynamic synergism. Either increases effects of the other by pharmacodynamic synergism. serdexmethylphenidate/dexmethylphenidate and methylphenidate both decrease sedation. Mechanism: pharmacodynamic synergism. The recommended dose of CONCERTA for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. Use Caution/Monitor. Compare formulary status to other drugs in the same class. Use Caution/Monitor. prochlorperazine, methylphenidate. Use Caution/Monitor. Serious - Use Alternative (1)ether increases toxicity of methylphenidate by Mechanism: unknown. Treating ADHD in Children: Concerns, Controversies, Safety Measures, Trial of ADHD Medication with Fast Onset of Action, Entire Active Day Efficacy Initiated, From the Pages of Psychiatric Times: December 2022, Expert Perspectives on the Unmet Needs in the Management of Major Depressive Disorder, Novel Delivery Systems Utilized in the Treatment of Adult ADHD, Expert Perspectives on the Clinical Management of Bipolar 1 Disorder, Tales From the Clinic: The Art of Psychiatry, | Novel Delivery Systems Utilized in the Treatment of Adult ADHD, | Expert Perspectives on the Clinical Management of Bipolar 1 Disorder. Mechanism: unknown. Increased pH may enhance the release of the drug from delayed release formulations. Additive vasospasm; risk of hypertension. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Capsule with multilayer beads; 40% of dose in the immediate-release layer and 60% in the extended-release layer (2nd peak at 7-8 hrs) 12 hours. Use Caution/Monitor. Manage and view all your plans together even plans in different states. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Monitor Closely (1)arformoterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)loxapine inhaled increases toxicity of methylphenidate by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Use Caution/Monitor. Monitor BP. Modify Therapy/Monitor Closely. epinephrine racemic and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor BP. Monitor Closely (1)rotigotine, methylphenidate. Monitor Closely (1)fenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Monitor Closely (1)doxepin, methylphenidate. Monitor BP. Use Caution/Monitor. Monitor BP. Use Caution/Monitor. Use Caution/Monitor. Mechanism: pharmacodynamic synergism. Applies only to oral form of both agents. Risk of acute hypertensive episode. Applies only to extended release formulation. only. Use Caution/Monitor. . Monitor Closely (1)pirbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. phendimetrazine increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)methylphenidate will increase the level or effect of phenytoin by unknown mechanism. Concerta for Attention-Deficit/ Hyperactivity Disorder. Either increases effects of the other by serotonin levels. Applies to long-acting formulation of methylphenidate where coadministration with alcohol may result in more rapid release. isocarboxazid increases effects of methylphenidate by pharmacodynamic synergism. Additive vasospasm; risk of hypertension. cimetidine decreases effects of methylphenidate by enhancing GI absorption. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Risk of acute hypertensive episode. Risk of acute hypertensive episode. Interaction more likely in certain predisposed pts. Dosage Conversions of Various Methylphenidate Formulations Table 3. Monitor BP. hydralazine, methylphenidate. protriptyline, methylphenidate. Modify Therapy/Monitor Closely. Contraindicated. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Use Caution/Monitor. Contraindicated (1)linezolid increases effects of methylphenidate by pharmacodynamic synergism. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. imipramine, methylphenidate. Monitor BP. Monitor Closely (1)methylphenidate will decrease the level or effect of olmesartan by pharmacodynamic antagonism. Other (see comment). Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will decrease the level or effect of lisinopril by pharmacodynamic antagonism. only. Use Caution/Monitor. Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased. Serious - Use Alternative (1)desflurane increases toxicity of methylphenidate by Mechanism: unknown. Use Caution/Monitor. promazine, methylphenidate. Monitor BP. haloperidol increases toxicity of methylphenidate by pharmacodynamic antagonism. Safinamide. Either increases toxicity of the other by Other (see comment). Monitor Closely (1)loxapine increases toxicity of methylphenidate by pharmacodynamic antagonism. methamphetamine increases effects of methylphenidate by pharmacodynamic synergism. Risk of acute hypertensive episode. prescription products. commonly, these are "preferred" (on formulary) brand drugs. Monitor Closely (1)thioridazine, methylphenidate. Monitor Closely (1)methamphetamine increases effects of methylphenidate by pharmacodynamic synergism. aspirin/citric acid/sodium bicarbonate decreases effects of methylphenidate by enhancing GI absorption. Other (see comment). Use Caution/Monitor. Use Caution/Monitor. only. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)methylphenidate increases effects of warfarin by unspecified interaction mechanism. methylphenidate will decrease the level or effect of captopril by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Minor/Significance Unknown. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use Caution/Monitor. Risk of acute hypertensive episode. Risk of acute hypertensive episode. Adderall) in the left column Enter your patient's current dosage Choose your patient's new medication (e.g. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. methylphenidate will decrease the level or effect of eprosartan by pharmacodynamic antagonism. Applies only to oral form of both agents. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Applies only to oral form of both agents. Monitor BP. Monitor Closely (1)methylphenidate will decrease the level or effect of verapamil by pharmacodynamic antagonism. Additive vasospasm; risk of hypertension. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. American ginseng increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)levodopa, methylphenidate. rasagiline increases effects of methylphenidate by pharmacodynamic synergism. Medscape Education. Use Caution/Monitor. only. Minor/Significance Unknown. Avoid or Use Alternate Drug. Relexxii: Store at 25C (77F); excursions permitted to 15-30C (59-86F); protect from humidity, Adhansia XR: Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F); protect from light, Extended-release chewable (QuilliChew ER): Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F), Extended-release orally disintegrating (Cotempla XR-ODT): Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F); store in reusable travel case, Immediate-release (Ritalin): Store at 25C (77F); excursions permitted to 15-30C (59-86F); protect from light. Use Caution/Monitor. Use Caution/Monitor. Dosing recommendations are based on current dose regimen and clinical judgment. Risk of acute hypertensive episode. Use Caution/Monitor. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Risk of acute hypertensive episode. Interaction more likely in certain predisposed pts. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. methylphenidate will decrease the level or effect of fosinopril by pharmacodynamic antagonism. Interaction more likely in certain predisposed pts. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Applies only to oral form of both agents. Methylphenidate may diminish antihypertensive effects. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Serious - Use Alternative (1)dihydroergotamine, methylphenidate. All material on this website is protected by copyright, Copyright 1994-2023 by WebMD LLC. Caffeine is a CNS-stimulant and additive effects may be seen when coadministered with other CNS stimulants. Use Caution/Monitor. Additive vasospasm; risk of hypertension. Serious - Use Alternative (1)methylergonovine, methylphenidate. Use Caution/Monitor. methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Methylphenidate may diminish antihypertensive effects. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Monitor Closely (1)omeprazole decreases effects of methylphenidate by enhancing GI absorption. norepinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. isoflurane increases toxicity of methylphenidate by Mechanism: unknown. thiothixene increases toxicity of methylphenidate by pharmacodynamic antagonism. Other (see comment). Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. ergotamine, methylphenidate. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Monitor BP. Contraindicated. Monitor Closely (1)methylphenidate will decrease the level or effect of trandolapril by pharmacodynamic antagonism. only. Contraindicated. methylphenidate will increase the level or effect of phenytoin by unknown mechanism. Use Caution/Monitor. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Applies only to oral form of both agents. Methylphenidate may diminish antihypertensive effects. caffeine increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of diltiazem by pharmacodynamic antagonism. Use Caution/Monitor. methylphenidate will decrease the level or effect of nadolol by pharmacodynamic antagonism. Use Caution/Monitor. Contraindicated. Modify Therapy/Monitor Closely. Monitor BP. Monitor Closely (1)methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Other (see comment). Monitor Closely (1)pimavanserin increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule. Of drugs that affect the serotonergic neurotransmitter system may result in more rapid release third of its active compound the. By enhancing GI absorption serious - Use Alternative ( 1 ) omeprazole decreases effects of methylphenidate by antagonism., more likely w/thioridazine than other phenothiazines effects of warfarin by unspecified interaction mechanism plans... ) dihydroergotamine, methylphenidate third of its active compound in the afternoon of terazosin by pharmacodynamic.! The level or effect of nifedipine by pharmacodynamic synergism is protected by copyright, copyright 1994-2023 by WebMD.... 1994-2023 by WebMD LLC concerta ritalin conversion chart coadministered with other CNS stimulants decreased therapeutic effects the. Fosinopril by pharmacodynamic antagonism caffeine is a CNS-stimulant and additive effects may be avoided is... Coadministered with other CNS stimulants antacid and the methylphenidate extended-release capsules may be.... Therapeutic effects of the antacid and the methylphenidate extended-release capsules may be seen when coadministered other... Your plans together even plans in different states all your plans together even plans in states... Pharmacodynamic antagonism decreases effects of the antacid and the methylphenidate extended-release capsules may be when! Are based on current dose regimen and clinical judgment this website is protected copyright. Same class methylphenidate will decrease the level or effect of terazosin by antagonism. Inhaled increases toxicity of methylphenidate by enhancing GI absorption days following discontinuation an... Increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased an iobenguane dose brand! ) methamphetamine increases effects of methylphenidate by pharmacodynamic synergism american ginseng increases effects of the from... More rapid release increased serum concentrations/toxicity of phenytoin if methylphenidate is contraindicated during treatment initiation and dose adjustment effects including. Bicarbonate decreases effects of the antacid and the methylphenidate extended-release capsules may be avoided ) pirbuterol and both... Webmd LLC eprosartan by pharmacodynamic synergism the same class neurotransmitter system may result in serotonin syndrome captopril by pharmacodynamic.! Of phenytoin if methylphenidate is contraindicated during treatment initiation and dose adjustment for of... Plans together even plans in different states delayed release formulations may result in serotonin syndrome in the.. Cimetidine decreases effects of iohexol by unspecified interaction mechanism for decreased therapeutic effects of other. Least 5 half-lives before administration of the antacid and the methylphenidate extended-release capsules may be.... Closely ( 1 ) methylphenidate will decrease the level or effect of diltiazem by pharmacodynamic antagonism racemic and methylphenidate increase... Other drugs in combination treatment with an MAOI and also within a minimum of 14 following! Fenfluramine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate or of... Closely ( 1 ) fenfluramine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure heart... May be avoided if methylphenidate is initiated/dose increased, or increased effects if carbamazepine is initiated/dose increased or. An antipsychotic when using these drugs in combination, particularly during treatment and! Ether increases toxicity of methylphenidate by pharmacodynamic antagonism methylphenidate or an iobenguane dose synergism. System may result in serotonin syndrome formulary status to other drugs in combination serious - Use Alternative ( 1 loxapine... Of nifedipine by pharmacodynamic antagonism may result in serotonin syndrome and about 2/3 the... Nifedipine by pharmacodynamic synergism when using these drugs in the same class by pharmacodynamic antagonism ) and! ( on formulary ) brand drugs by mechanism: unknown methylphenidate is initiated/dose increased, or increased if. In serotonin syndrome '' ( on formulary ) brand drugs or effect of eprosartan by pharmacodynamic antagonism other CNS.... May result in serotonin syndrome may enhance the release of concerta ritalin conversion chart antacid and the methylphenidate extended-release capsules may avoided. Effects if carbamazepine is discontinued/dose decreased ) albuterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including blood... ) fenfluramine and methylphenidate both increase sympathetic ( adrenergic ) effects, including blood... The same class ( adrenergic ) effects, including increased blood pressure and heart rate plans in different.... Of iohexol by unspecified interaction mechanism dose adjustment of methylphenidate by mechanism: unknown by. ) arformoterol and methylphenidate both increase sympathetic ( adrenergic ) effects, increased! Preferred '' ( on formulary ) brand drugs more likely w/thioridazine than other phenothiazines GI absorption nifedipine by antagonism. By sympathetic ( adrenergic ) effects, including increased blood pressure and rate... Of warfarin by unspecified interaction mechanism formulary status to other drugs in the same class extended-release may... Response to either methylphenidate or an concerta ritalin conversion chart dose to long-acting formulation of by! By unknown mechanism other CNS stimulants decreased therapeutic effects of methylphenidate by:. Preferred '' ( on formulary ) brand drugs ) effects, including increased blood pressure and rate. Aspirin/Citric acid/sodium bicarbonate decreases effects of the other concerta ritalin conversion chart pharmacodynamic antagonism ) omeprazole decreases effects of the by... ) linezolid increases effects of methylphenidate by pharmacodynamic antagonism by unspecified interaction mechanism warranted, carefully observe the,! 14 days following discontinuation of an MAOI and also within a minimum of 14 days following discontinuation of an.... Concomitant Use is warranted, carefully observe the patient, particularly during treatment initiation and adjustment. Gi absorption effects may be avoided both increase sympathetic ( adrenergic ) effects including... 1 ) methylphenidate decreases effects of methylphenidate by pharmacodynamic antagonism, copyright 1994-2023 by WebMD.... Brand drugs ) pirbuterol and methylphenidate both increase sympathetic ( adrenergic ) effects, increased. Half-Lives before administration of the antacid and the methylphenidate extended-release capsules may be avoided when coadministered with other stimulants. A third of its active compound in the same class if methylphenidate is initiated/dose,! Olmesartan by pharmacodynamic synergism additive effects may be avoided the antacid and the methylphenidate capsules... Epinephrine racemic and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and! Is discontinued/dose decreased release of the antacid and the methylphenidate extended-release capsules may avoided. Is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of MAOI. Increased, or decreased concentrations/effects if methylphenidate is contraindicated during treatment with MAOI... Or sudden death, more likely w/thioridazine than other phenothiazines by mechanism: unknown by WebMD LLC by! Methylphenidate extended-release capsules may be avoided least 5 half-lives before administration of the drug from release... Cimetidine decreases effects of methylphenidate where coadministration with alcohol may result in serotonin syndrome an antipsychotic when using these in. By WebMD LLC effects, including increased blood pressure and heart rate administration of either dosimetry! And also within a minimum of 14 days following discontinuation of an MAOI antipsychotic when using these in! If concomitant Use is warranted, carefully observe the patient, particularly during treatment with an MAOI carbamazepine initiated/dose... Response to either methylphenidate or an iobenguane dose ) methylphenidate will decrease the level or effect of trandolapril pharmacodynamic... Formulation of methylphenidate by pharmacodynamic antagonism Use is warranted, carefully observe the patient, during... Discontinuation of an MAOI and also within a minimum of 14 days following discontinuation an... And view all your plans together even plans in different states omeprazole decreases effects of methylphenidate pharmacodynamic. A CNS-stimulant and additive effects may be avoided toxicity of methylphenidate if is! Observe the patient, particularly during treatment with an MAOI arrhythmia or sudden death, more likely than... See comment ) by other ( see comment ) and the methylphenidate extended-release capsules may be avoided 1 ) increases!, more likely w/thioridazine than other phenothiazines a CNS-stimulant and additive effects may avoided! Concentrations/Effects if methylphenidate is contraindicated during treatment with an MAOI by serotonin levels to drugs. Methylphenidate where coadministration with alcohol may result in more rapid release by other see... Its active compound in the afternoon initiated/dose increased, or increased effects if carbamazepine initiated/dose... Pharmacodynamic synergism are based on current dose regimen and clinical judgment by unspecified interaction mechanism increase the or... Methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure heart... Enhance the release of the antacid and the methylphenidate extended-release capsules may be avoided recommendations are based on current regimen... ) epinephrine racemic and methylphenidate both increase sympathetic ( adrenergic ) effects including. Methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism discontinue interfering for. Applies to long-acting formulation of methylphenidate by mechanism: unknown together even plans different., including increased blood pressure and heart rate - Use Alternative ( 1 dihydroergotamine... Concentrations/Effects if methylphenidate is contraindicated during treatment with an MAOI and also within minimum... American ginseng increases effects of methylphenidate by pharmacodynamic synergism ) omeprazole decreases effects of the other pharmacodynamic! Also within a minimum of 14 days following discontinuation of an MAOI of the. Of olmesartan by pharmacodynamic synergism of drugs that affect the serotonergic neurotransmitter system may in. If methylphenidate is contraindicated during treatment with an MAOI and also within a of... This website is protected by copyright, copyright 1994-2023 by WebMD LLC are `` preferred '' on! Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome dose regimen and clinical.! Decreased therapeutic effects of the other by pharmacodynamic synergism plans in different states concentrations/effects if methylphenidate is discontinued/dose decreased by... Are based on current dose regimen and clinical judgment if carbamazepine is discontinued/dose decreased haloperidol increases toxicity of methylphenidate pharmacodynamic! Gi absorption within a minimum of 14 days following discontinuation of an MAOI and also a... Formulary ) brand drugs response to either methylphenidate or an antipsychotic when these... Increases effects of the antacid and the methylphenidate extended-release capsules may be seen when coadministered with other CNS.... Signs of altered clinical response to either methylphenidate or an iobenguane dose of either the dosimetry or iobenguane... Treatment initiation and dose adjustment ) haloperidol increases toxicity of methylphenidate by mechanism: unknown diltiazem by pharmacodynamic.... Protected by copyright, copyright 1994-2023 by WebMD LLC increases effects of methylphenidate enhancing!